Vaccines Development
Protective immunity to ____________ bacteria involves development of __ antibody response to a ______________ (PS) antigen, interactions with _ and B lymphocytes, and ____ defense mechanisms. Polysaccharide ________ have evolved as a ______ class of inactivated subunit _______, composed of long chains __ sugar molecules that make __ the surface capsule of _______ bacteria.
As T-cell independent ________, including polysaccharide vaccines, are ___ consistently immunogenic in children < 2 years of age, _________ vaccines have come into ___ since conjugation changes the ______ response from T-cell independent __ T-cell dependent, leading to _________ immunogenicity in infants and ________ booster response to multiple _____ of vaccine.
Premas collaborates with ________ for development of polysaccharide ________ and conjugate vaccines, pilot _______, process development for fermentation ___ purification, large scale production ___ analytical characterization with our _______ and partners.
Two vaccine candidate ___________ programs that we are _______ in have progressed to _____ trials. Apart from PS ___________ program, Premas has developed ________ vaccine candidates and their ________ reagents for human and ______ use. We’ve completed over 25 projects associated with such _____________ programs.
Premas has completed _________, Viral, Anti-Helminthic, Dental (ScFV _____) vaccines and their development. ____ of them include RSV ________ antigens, VLPs, Glyco-proteins (antigenic), _________, etc. We have served ___ animal health programs for ______, porcine, canine, etc vaccine ____________. Premas has developed a ___________ carrier protein CRM 197 _____ the E coli expression ________ as a secretory protein. ___________ and functional characterization demonstrate _____________ and bettering of effect ____ the existing commercially available _________.
